Did you know that your browser is out of date?
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
Antitrust Considerations for Biosimilar Reverse Payment Litigation – Not So Similar Afterall?
03 June 2020
Dr. Sheng Li
Senior Consultant Dr. Sheng Li and former Senior Consultant Dr. Omar Robles analyze the differences in antitrust considerations for biologics and small-molecule drugs in the American Bar Association (ABA) Section of Antitrust Law’s Civil Practice and Procedure Committee’s Young Lawyers Advisory Panel newsletter Perspectives in Antitrust. Dr Li and Dr. Robles discuss the potential economic implications of biosimilar reverse payment litigation focusing on class certification, market power, competitive effects, and economic damages.
Biologics and biosimilars open new treatment possibilities for patients as well as potentially new competitive considerations for antitrust regulators and practitioners.
Dr. Sheng Li and Dr. Omar Robles
Authors